Anixa Biosciences Inc (ANIX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.37
- As of
Kresmion compiles this page from ANIX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Anixa Biosciences Inc (ANIX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-09-09.
See the full ANIX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANIX on one page. Preview it with sample data, then open it live with a free account.
Preview the ANIX dossierActive events for ANIX
- mediumEarnings above estimates
Q3-2026: Beat consensus by 8.8%, EPS $-0.08 vs $-0.0877 estimate
- mediumEarnings above estimates
Q1-2026: Beat consensus by 17.4%, EPS $-0.08 vs $-0.0969 estimate
- mediumEarnings above estimates
Q2-2026: Beat consensus by 21.6%, EPS $-0.07 vs $-0.0893 estimate
- high13F: large increase
Point72 Asset Management, L.P. added +100% to ANIX (2026Q1)
- medium13F: new position
TWO SIGMA INVESTMENTS, LP new position in ANIX
FREE, NO ACCOUNT
Every event on ANIX, as it fires
New filings, 13F moves and cross asset events on ANIX land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ANIX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03528H109 · 2026Q2 | $166K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 03528H109 · 2026Q2 | $89K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ANIX
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ANIX against its peers
ANIX's return on equity of -72.1% ranks in the 53rd percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-01-31 and 2025-12-31.
| Metric | ANIX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 3.6M | n/a | 15 |
| Operating margin | n/a | -326.6% | n/a | 13 |
| Net margin | n/a | -363.4% | n/a | 14 |
| Return on equity | -72.1% | -87.9% | 53 | 17 |
Peers (24): OKUR, VANI, IMUX, VXRT, LENZ, TVGN, CLLS, ENGN, CBUS, BETRF, VYGR, PYPD, BDTX, UNCY, ICCC, NERV, VTVT, NTHI, NRXP, COYA, NRXS, GNLX, INO, KZIA. Left out: TNXP (no annual filing). Fiscal periods ending between 2025-01-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ANIX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ANIX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ANIX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.